产品描述

Merestinib, also known as LY2801653, is a n orally available, small molecule inhibitor of the proto-oncogene c-Met (mesenchymal-epithelial transition, also known as hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. c-Met inhibitor LY2801653 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. This agent has potent anti-tumor efficacy in mono- and combination therapy in a broad range of cancers.

化学结构

化学名称

N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

SMILES Code

O=C(C1=CC=C(C)N(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=CC5=C(N(C)N=C5)C=C4C6=CNN=C6)C(F)=C3

基本信息

产品编号:XM706  产品名称:Merestinib (LY2801653)  别名:LY-2801653; LY 2801653; LY2801653; Merestinib  CAS#:1206799-15-6 (free base)  分子式:C30H22F2N6O3  精确分子量:552.17215  分子量:552.53  纯度:>98%

物化性质

该产品只供科研使用，不能给病人提供。